Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D, Apperley JF.

Blood. 2019 Nov 13;134(Supplement_1):26. doi: 10.1182/blood-2019-131500.

PMID:
31724022
2.

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.

Smith CC, Levis MJ, Perl AE, Martinelli G, Neubauer A, Berman E, Montesinos P, Baer MR, Larson RA, Chou WC, Yokoyama H, Recher C, Yoon SS, Hill JE, Rosales M, Bahceci E.

Blood. 2019 Nov 13;134(Supplement_1):14. doi: 10.1182/blood-2019-122620.

PMID:
31723984
3.

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution.

Joffe E, Kumar A, Zheng S, Uppal M, Bantilan KS, Atteberry P, Straus DJ, Palomba ML, Noy A, Horwitz SM, Moskowitz AJ, Hamlin PA, Matasar MJ, Batlevi CL, von Keudell GR, Dogan A, Younes A, Zelenetz AD.

Blood. 2019 Nov 13;134(Supplement_1):22. doi: 10.1182/blood-2019-129563.

PMID:
31724028
4.

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).

Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG.

Blood. 2019 Nov 13;134(Supplement_1):34. doi: 10.1182/blood-2019-131847.

PMID:
31724006
5.

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.

Shanafelt TD, Wang V, Kay NE, Hanson CA, O'Brien SM, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre S, Barr PM, Cashen AF, Mato AR, Singh A, Mullane MP, Little RF, Erba HP, Stone RM, Litzow M, Tallman MS.

Blood. 2019 Nov 13;134(Supplement_1):33. doi: 10.1182/blood-2019-126824.

PMID:
31723996
6.

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).

Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, Follows G, Karlsson K, Ghia P, Corbett G, Walker P, Egyed M, Jurczak W, Salles G, Janssens A, Cymbalista F, Wierda WG, Coutre S, Pagel JM, Skarbnik A, Kamdar M, Woyach J, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC.

Blood. 2019 Nov 13;134(Supplement_1):31. doi: 10.1182/blood-2019-128404.

PMID:
31724010
7.

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.

Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG.

Blood. 2019 Nov 13;134(Supplement_1):35. doi: 10.1182/blood-2019-121424.

PMID:
31724017
8.

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines.

Schuster SJ, Bartlett NL, Assouline S, Yoon SS, Bosch F, Sehn LH, Cheah CY, Shadman M, Gregory GP, Ku M, Wei MC, Yin S, Kwan A, Yousefi K, Hernandez G, Li CC, O'Hear C, Budde LE.

Blood. 2019 Nov 13;134(Supplement_1):6. doi: 10.1182/blood-2019-123742.

PMID:
31723992
9.

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial.

Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink AM, Schilhabel A, Stübig T, Brüggemann M, Jiang Y, Schary W, Eichhorst BF, Wendtner CM, Tausch E, Kreuzer KA, Langerak AW, Goede V, Böttcher S, Stilgenbauer S, Kneba M, Hallek M.

Blood. 2019 Nov 13;134(Supplement_1):36. doi: 10.1182/blood-2019-125825.

PMID:
31724026
10.

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission.

Murdock HM, Kim HT, Hambley B, Vachhani P, Denlinger N, Gier SH, Cho C, Perales MA, Koreth J, Ho VT, Soiffer RJ, McCurdy SR, Carroll M, Vasu S, Wang ES, Gondek LP, Devine S, Alyea EP, Gibson CJ, Lindsley RC.

Blood. 2019 Nov 13;134(Supplement_1):48. doi: 10.1182/blood-2019-125967.

PMID:
31724009
11.

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci A, Huguet F, Gardembas M, Ianotto JC, Escoffre-Barbe M, Coiteux V, Varet B, Morisset S, Mahon FX.

Blood. 2019 Nov 13;134(Supplement_1):28. doi: 10.1182/blood-2019-123719.

PMID:
31723981
12.

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.

Rea D, Nicolini FE, Tulliez M, Rousselot P, Gardembas M, Etienne G, Guilhot F, Guilhot J, Guerci A, Escoffre-Barbe M, Legros L, Villemagne B, Guillerm G, Noel MP, Coiteux V, Pignon JM, Mahon FX.

Blood. 2019 Nov 13;134(Supplement_1):30. doi: 10.1182/blood-2019-124408.

PMID:
31724000
13.

Stem Cell Transplantation for Diamond-Blackfan Anemia. a Retrospective Study on Behalf of Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplantation Group (EBMT).

Miano M, Eikema DJ, de la Fuente J, Bosman P, Ghavamzadeh A, Smiers F, Sengeløv H, Yesilipek A, Formankova R, Bader P, Díaz Pérez MÁ, Bertrand Y, Niemeyer C, Bron D, Ansari M, Bykova TA, Lanino E, Rovelli A, Gozdzik J, Satti TM, Bodova I, Wölfl M, Rocha VG, Mellgren K, Rascon J, Lange A, Meisel R, Beguin Y, Mozo Y, Kriván G, Sirvent A, Bruno B, Onofrillo D, Risitano AM, Peffault de Latour R, Dufour C.

Blood. 2019 Nov 13;134(Supplement_1):44. doi: 10.1182/blood-2019-124644.

PMID:
31724018
14.

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

Tanaka T, Morita K, Wang F, Little L, Gumbs C, Matthews J, DiNardo CD, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Garcia-Manero G, Futreal PA, Takahashi K.

Blood. 2019 Nov 13;134(Supplement_1):17. doi: 10.1182/blood-2019-122274.

PMID:
31724013
15.

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.

Statler A, Hobbs BP, Radivoyevitch T, Siebenaller C, Mukherjee S, Advani AS, Gerds AT, Nazha A, Patel BJ, Carraway HE, Sekeres MA.

Blood. 2019 Nov 13;134(Supplement_1):16. doi: 10.1182/blood-2019-130319.

PMID:
31724007
16.

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.

Li X, Kositsky R, Reddy A, Love C, Naresh K, Koff JL, Nystrand I, Leppä S, Pasanen A, Karjalainen-Lindsberg ML, Dunkel J, Kovanen P, Qin Q, Bhagat G, Leeman-Neill RJ, Goswami RS, Wildeman S, Delabie J, Burack R, Evans AG, Amador C, Yuan J, Qureishi HN, Li S, Xu J, Yin CC, Gang AO, Norgaard PH, Pedersen MØ, Chan JY, Cheah DMZ, Ong SY, Cheng CL, Lee L, Paulua F, Ondrejka SL, Hsi ED, Czader M, Wang L, Landis A, Churnetski MC, Jaye DL, Flowers CR, McCall CM, Neff J, McKinney MS, Fedoriw Y, Powers E, Montgomery ND, Bogusz AM, Stafford Hintz A, Kovach AE, Reddy N, Thompson Arildsen MA, Mason EF, Juskevicius R, Choi W, Au-Yeung R, Tse E, Sarno V, Chadburn A, Lopez R, Chapman JR, Behdad A, Goldschmidt N, Goodlad J, Burton C, Pillai R, Louissaint A, Soliman DS, Panea R, Dave T, Xiong B, Smith E, Dave S.

Blood. 2019 Nov 13;134(Supplement_1):19. doi: 10.1182/blood-2019-130255.

PMID:
31723982
17.

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Sauer T, Hänel M, Herbst R, Schäfer-Eckart K, Noppeney R, Jost E, Brümmendorf TH, Krause SW, Kunzmann V, Einsele H, Scholl S, Hochhaus A, Fransecky LR, Kaufmann M, Neubauer A, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Klein S, Von Bonin M, Middeke JM, Thiede C, Stoelzel F, Schetelig J, Ehninger G, Baldus CD, Müller-Tidow C, Platzbecker U, Serve H, Bornhäuser M.

Blood. 2019 Nov 13;134(Supplement_1):13. doi: 10.1182/blood-2019-123717.

PMID:
31724019
18.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS.

Blood. 2019 Nov 13;134(Supplement_1):32. doi: 10.1182/blood-2019-127506.

PMID:
31723987
19.

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).

Lindsley RC, Gibson CJ, Murdock HM, Stone RM, Cortes JE, Uy GL, Lin TL, Ritchie EK, Prebet T, Ryan RJ, Faderl S, Lancet JE.

Blood. 2019 Nov 13;134(Supplement_1):15. doi: 10.1182/blood-2019-124500.

PMID:
31723998
20.

Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis.

Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE.

Blood. 2019 Nov 13;134(Supplement_1):42. doi: 10.1182/blood-2019-123699.

PMID:
31724003

Supplemental Content

Support Center